BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 17652816)

  • 1. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: a prospective follow-up study.
    Sieswerda E; Kremer LC; Vidmar S; De Bruin ML; Smibert E; Sjöberg G; Cheung MM; Weintraub RG
    Pediatr Blood Cancer; 2010 Apr; 54(4):579-84. PubMed ID: 20014238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal NT-pro-BNP levels in asymptomatic long-term survivors of childhood cancer treated with anthracyclines.
    Mavinkurve-Groothuis AM; Groot-Loonen J; Bellersen L; Pourier MS; Feuth T; Bökkerink JP; Hoogerbrugge PM; Kapusta L
    Pediatr Blood Cancer; 2009 May; 52(5):631-6. PubMed ID: 19127569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management.
    Barry E; Alvarez JA; Scully RE; Miller TL; Lipshultz SE
    Expert Opin Pharmacother; 2007 Jun; 8(8):1039-58. PubMed ID: 17516870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients.
    Anderson B
    Pediatr Blood Cancer; 2005 Jun; 44(7):584-8. PubMed ID: 15700251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer.
    Jensen BV
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S15-21. PubMed ID: 16781285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Anthracycline-induced cardiotoxicity: monitoring and prevention of the lesion].
    Orditura M; De Vita F; Ciaramella F; Catalano G
    Ann Ital Med Int; 1994; 9(4):243-8. PubMed ID: 7893575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
    Robert J
    Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials.
    van Dalen EC; van den Brug M; Caron HN; Kremer LC
    Eur J Cancer; 2006 Dec; 42(18):3199-205. PubMed ID: 17011186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of anthracycline-induced cardiotoxicity in children: the evidence.
    van Dalen EC; Caron HN; Kremer LC
    Eur J Cancer; 2007 May; 43(7):1134-40. PubMed ID: 17383867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticancer agents and cardiotoxicity.
    Ng R; Better N; Green MD
    Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity.
    Jones RL
    Expert Rev Cardiovasc Ther; 2008 Nov; 6(10):1311-7. PubMed ID: 19018683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring for anthracycline cardiotoxicity.
    Lipshultz SE; Sanders SP; Goorin AM; Krischer JP; Sallan SE; Colan SD
    Pediatrics; 1994 Mar; 93(3):433-7. PubMed ID: 7818624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracycline-induced cardiomyopathy.
    Keefe DL
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):2-7. PubMed ID: 11552224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of mtDNA lesions in anthracycline cardiotoxicity.
    Lebrecht D; Walker UA
    Cardiovasc Toxicol; 2007; 7(2):108-13. PubMed ID: 17652814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthracycline cardiotoxicity in childhood.
    Ruggiero A; Ridola V; Puma N; Molinari F; Coccia P; De Rosa G; Riccardi R
    Pediatr Hematol Oncol; 2008 Jun; 25(4):261-81. PubMed ID: 18484471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.